Multiple sclerosis (MS) is an autoimmune disorder. In this disease, the body’s immune system attacks and destroys the cells that cover and protect nerves. This study will test the safety of a new drug called RG2077 that is designed to treat MS. The study will not determine whether RG2077 is effective in treating MS, only whether it is safe to use in patients with MS.

Study hypothesis: Treatment with RG2077 will arrest SLE if administered early in the course of MS and decrease accumulation of lesions on MRI.

Effective treatment of autoimmune disorders is likely to arise not from improved immunosuppression, but from improved understanding of the normal mechanisms that generate and maintain self-tolerance. This dose-escalation study will evaluate the safety of RG2077 (CTLA4-IgG4m) in patients with MS. RG2077 may block a T cell costimulation pathway central to the pathophysiology of MS.

Twenty-four patients with MS will be enrolled in this study. Each patient will participate in the study for 4 months. Participants will be assigned to one of four groups. Each group will receive a different dose of RG2077. Patients will be monitored for possible side effects of RG2077.

Ages Eligible for Study:  18 Years   -   55 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

• Confirmed diagnosis of MS, defined as an MRI consistent with MS plus two separate clinical events, or one clinical event and MRI consistent with demyelination plus a second MRI demonstrating new lesions
• Have declined all FDA approved therapies for MS